Abstract
ObjectiveLow-magnitude high-frequency vibration (LMHFV) has been reported to be capable of promoting osteoblast proliferation and differentiation. Reduced osteoblast activity and impaired bone formation were related to diabetic bone loss. We investigated the potential protective effects of LMHFV on high-glucose (HG)-induced osteoblasts in this study. In addition, the assessment of LMHFV treatment for bone loss attributed to diabetes was also performed in vivo.MethodMC3T3-E1 cells induced by HG only or treated with LMHFV were treated in vitro. The experiments performed in this study included the detection of cell proliferation, migration and differentiation, as well as protein expression. Diabetic bone loss induced by streptozotocin (STZ) in rats was established. Combined with bone morphometric, microstructure, biomechanical properties and matrix composition tests, the potential of LMHFV in treating diabetes bone loss was explored.ResultsAfter the application of LMHFV, the inhibiting effects of HG on the proliferation, migration and differentiation of osteoblasts were alleviated. The GSK3β/β-catenin pathway was involved in the protective effect of LMHFV. Impaired microstructure and biomechanical properties attributed to diabetes were ameliorated by LMHFV treatment. The improvement of femur biomechanical properties might be associated with the alteration of the matrix composition by the LMHFV.ConclusionLMHFV exhibited a protective effect on osteoblasts against HG by regulating the proliferation, migration and differentiation of osteoblasts. The function of promoting bone formation and reinforcing bone strength made it possible for LMHFV to alleviate diabetic bone loss.
Highlights
IntroductionPrimary osteoporosis is associated with menopause and old age, while secondary osteoporosis is generally
Low-magnitude high-frequency vibration (LMHFV) exhibited a protective effect on osteoblasts against HG by regulating the proliferation, migration and differentiation of osteoblasts
Since variations in cell proliferation may be attributed to variations in the cell cycle, this study further investigated the cell cycle changes of MC3T3-E1 cells under different treatments using flow cytometry
Summary
Primary osteoporosis is associated with menopause and old age, while secondary osteoporosis is generally. Fu et al J Orthop Surg Res (2021) 16:650 in bone microstructure and the occurrence of fragile bones [4]. Even antidiabetic drugs such as insulin and metformin were reported to exert side effects on bone and cause increased risk of fracture [5]. Evidence from clinical trials supported that LMHFV could increase bone density in postmenopausal women [9]. LMHFV might help mitigate bone loss induced by diabetes
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
